South Dakota Investment Council lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 8.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 57,880 shares of the medical research company’s stock after selling 5,458 shares during the period. South Dakota Investment Council’s holdings in Edwards Lifesciences were worth $4,996,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. RMG Wealth Management LLC acquired a new stake in Edwards Lifesciences in the first quarter valued at approximately $26,000. Pin Oak Investment Advisors Inc. bought a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $26,000. GK Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth approximately $26,000. TrinityBridge Ltd acquired a new position in shares of Edwards Lifesciences during the second quarter worth approximately $27,000. Finally, Meeder Asset Management Inc. raised its position in shares of Edwards Lifesciences by 175.2% during the first quarter. Meeder Asset Management Inc. now owns 366 shares of the medical research company’s stock worth $29,000 after purchasing an additional 233 shares during the period. Institutional investors own 79.46% of the company’s stock.
Edwards Lifesciences Price Performance
Shares of NYSE:EW opened at $105.17 on Thursday. The company has a market capitalization of $60.47 billion, a P/E ratio of 35.86, a price-to-earnings-growth ratio of 2.81 and a beta of 0.85. The company’s 50-day moving average is $91.51 and its 200 day moving average is $86.68. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.86 and a current ratio of 4.60. Edwards Lifesciences Corporation has a fifty-two week low of $74.66 and a fifty-two week high of $108.00.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.06. The business had revenue of $1.72 billion during the quarter, compared to the consensus estimate of $1.68 billion. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.06%. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.67 earnings per share. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post 3.01 earnings per share for the current year.
Insider Activity at Edwards Lifesciences
In other news, VP Donald Bobo, Jr sold 48,900 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $103.05, for a total transaction of $5,039,145.00. Following the completion of the sale, the vice president owned 22,798 shares in the company, valued at $2,349,333.90. This trade represents a 68.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $104.25, for a total transaction of $64,530.75. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $4,173,544.50. The trade was a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 53,945 shares of company stock valued at $5,498,306 over the last quarter. 0.31% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Several analysts recently issued reports on the stock. Deutsche Bank set a $104.00 price target on shares of Edwards Lifesciences in a research report on Tuesday, October 27th. TD Cowen boosted their price target on shares of Edwards Lifesciences from $117.00 to $121.00 and gave the stock a “buy” rating in a report on Wednesday, November 11th. Royal Bank Of Canada boosted their price target on shares of Edwards Lifesciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Barclays upped their price objective on shares of Edwards Lifesciences from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, November 5th. Finally, Sanford C. Bernstein increased their price objective on shares of Edwards Lifesciences from $99.00 to $106.00 and gave the company a “market perform” rating in a research note on Thursday, November 5th. Twenty-three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $109.88.
Check Out Our Latest Research Report on EW
Edwards Lifesciences Profile
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
Further Reading
- Five stocks we like better than Edwards Lifesciences
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
